Researchers at the Centre for Genomic Regulation in Barcelona discovered that a single, already licensed small molecule can stabilize nearly all mutated forms of the vasopressin V2 receptor (V2R), a G-protein-coupled receptor vital for cellular signaling. This breakthrough demonstrates the potential for pharmacological chaperones to rescue protein function across diverse mutations, offering a new paradigm for treating rare genetic diseases caused by protein misfolding or trafficking defects. The findings were published in Nature Structural & Molecular Biology.